Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 3Phase NA 2Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Completed 3Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Neoplasms 1331Breast Neoplasms 688Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 437Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 366Lymphoma, Non-Hodgkin 356Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 267Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 254Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Hodgkin Disease 193Carcinoma, Renal Cell 193Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Glioma 172Burkitt Lymphoma 172

Interventions

Lenalidomide 2siltuximab 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Receptors, Interleukin-6 1PVX-410 vaccine 1Interleukin 1 Receptor Antagonist Protein 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × Smoldering Multiple Myeloma × Clear all
NCT02492750 2020-03-25

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

Mayo Clinic

Phase 1 Completed
14 enrolled 12 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT01718899 2016-09-28

Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

OncoPep, Inc.

Phase 1 Completed
22 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡